See how the central venous catheter bundle, which is comprises of training, SOPs and ultrasonic vein locator, affects the quality of like of a childhood cancer patients.
- Conditions
- Neoplasms,
- Registration Number
- CTRI/2022/07/043720
- Lead Sponsor
- Cankids Kidscan
- Brief Summary
IV access is an important component of patient care, especially forthose who require long-term IV treatment like chemotherapy and supportive care.Many studies done in other parts of the world have documented the importance ofIV access for cancer care as part of routine practices. For pediatric patients,IV access is challenging because of their small caliber veins, anatomical variations, along with the child’sanxiety, and withdrawal add to the difficulty of vascular access. Childrenundergoing cancer treatment require IV access multiple times during theirtreatment. Trained personnel for IV access for pediatric cancer patients mayreduce the chances of multiple attempts, thus less pain and shorter durationfor vein puncher. There are many devices available for vein access includingthe ultrasound (US) guidance device for intravenous (IV) access. This has nowemerged as routine practice in many settings for central line placement and difficultperipheral IV access. This is an under-researched area in developing countrieslike India and the data for current practices lacks for most of the developingcountries. This study aims to explore the current practices in two cancercenters in New Delhi that provide treatment for pediatric cancer patients. Basedupon the findings from the baseline study, a center-specific intervention foreach participating center will be done. As an intervention, a Central VenousCatheter bundle (CVC Bundle) comprising of equipment, staff, training, SoPs, and an Ultrasound (USG) locator shall be used at the participatingcenter. The intervention CVC package will be developed building on the servicesavailable currently at the participating centre with support from Cankids. The impactof the intervention will be assessed by carrying out a post-intervention assessmentof phlebitis and quality of life in the participating centers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 90
- Require IV drugs on a regular basis for 4 weeks or more during treatment in the participating center.
- Consent to participate.
- Moribund and likely failure due to anatomical variation will be excluded from the study.
- Patients who have got multiple failures attempts previously or have a history of failed attempts for IV access.
- Patients who have got their IV access done at other than the participating center.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a. % CVC insertions of all VAD insertions 12 Weeks b. % VAD removed in 24 hours, 48 hours, 72 hours and 168 hours. 12 Weeks c. Number of attempts to insert VAD (including CVC). 12 Weeks
- Secondary Outcome Measures
Name Time Method a. VIP phlebitis score at 24 hours, 48 hours, 72 hours and 168 hours. 12 Weeks
Trial Locations
- Locations (1)
Safdarjung Hospital
🇮🇳Delhi, DELHI, India
Safdarjung Hospital🇮🇳Delhi, DELHI, IndiaDr Amitabh SinghPrincipal investigator8447594629doc.amitabh@gmail.com